This Article  • References  • Full text PDF  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Clinical Evidence and Genetic and Metabolic Background

Mohammed H. Moghadasian, DVM, MSc; Bruce M. McManus, MD, PhD, FRCPC; Jiri J. Frohlich, MD, FRCPC

Arch Intern Med. 1997;157(20):2299-2308.

Abstract
Many studies have demonstrated a strong association between elevated plasma total homocyst(e)ine levels and vascular diseases. Consequently, hyperhomocyst(e)inemia is now generally accepted as an independent risk factor for coronary artery disease. We critically reviewed the results of 35 human studies in which the levels of plasma total homocysteine were measured in patients with atherosclerotic diseases (n=4338) and in controls (n=22) 593). Total homocysteine levels were consistently higher in patients than in controls. The average of this increment among 23 case-control studies was 26%. New insights into the biochemical pathways of total homocysteine metabolism, the factors that influence total homocysteine levels, genetic contributions to hyperhomocyst(e)inemia, the pathogenesis of homocyst(e)ine-induced vascular damage, and current recommendations for treatment of hyperhomocyst(e)inemia were also reviewed. Various lines of evidence now link hyperhomocyst(e)inemia with vascular diseases. Although there are no data from double-blind, placebo-controlled clinical trials of treatment for hyperhomocyst(e)inemia, the strong epidemiologic and experimental evidence argues for treatment of hyperhomocyst(e)inemia; in fact, its treatment with low doses of vitamins is thought to be safe and is inexpensive.

Arch Intern Med. 1997;157:2299-2308

Author Affiliations
From the Healthy Heart Program (Drs Moghadasian and Frohlich and Cardiovascular Research Laboratory (Dr McManus), St Paul's Hospital and Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Pre-operative homocysteine levels and morbidity and mortality following cardiac surgery
Ranucci et al.
Eur Heart J 2009;30:995-1004.
ABSTRACT | FULL TEXT  

Ethnicity and peripheral artery disease
Bennett et al.
QJM 2009;102:3-16.
ABSTRACT | FULL TEXT  

Homocyst(e)ine and cardiovascular disease: a systematic review of the evidence with special emphasis on case-control studies and nested case-control studies
Ford et al.
Int J Epidemiol 2002;31:59-70.
ABSTRACT | FULL TEXT  

Pathophysiology of apolipoprotein E deficiency in mice: relevance to apo E-related disorders in humans
MOGHADASIAN et al.
FASEB J. 2001;15:2623-2630.
ABSTRACT | FULL TEXT  

Hyperhomocystinemia: A Risk Factor or a Consequence of Coronary Heart Disease?
Knekt et al.
Arch Intern Med 2001;161:1589-1594.
ABSTRACT | FULL TEXT  

Plasma Homocysteine and L-DOPA Metabolism in Patients with Parkinson Disease
Blandini et al.
Clin. Chem. 2001;47:1102-1104.
FULL TEXT  

Plasma Folate, Vitamin B12, and Homocyst(e)ine Concentrations in Preeclamptic and Normotensive Peruvian Women
Sanchez et al.
Am J Epidemiol 2001;153:474-480.
ABSTRACT | FULL TEXT  

Preventive health care, 2000 update: screening and management of hyperhomocysteinemia for the prevention of coronary artery disease events
Booth et al.
CMAJ 2000;163:21-29.
ABSTRACT | FULL TEXT